Objective: Diabetic foot ulcer now is main cause of chronic ulcer in Taiwan, as other countries. Unhealed ulcer will proceed to high level amputation, even morbidity and mortality. Fespixon cream is currently only one drug approved by TFDA in Diabetic foot ulcer treatment, and recently, also approved by national health insurance reimbursement. We will present our clinical experience in Fespixon cream in DFU and how to claim the reimbursement to national health insurance guideline.

Material & Methods:
We present 4 patients with unhealed DFU and claim the reimbursement to NHI. Each patient full filled the criteria in 1. Unhealed less than 50% in 3 months(photo), 2. Unless than 5 cm2, 3. HbA1C<8.5%, Albumin> 3mg/dl, ABI>0.9.

Results
Only 1 patients proved by NHI and gain the reimbursement from NHI, who healed in 1 months later. One patient was expired in pneumonia, The rest of 2 patients still received local wound care in clinics

Conclusion
Fulfilled the criteria of Fespixon cream guideline by NHI needs the wound care team provides detail wound recording, multidisciplinary team workup including endocrinologist, interventionist, wound care nursing staff and plastic reconstruction surgeon.